Allogene Therapeutics, Inc.
ALLO
$1.21
-$0.01-0.82%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -100.00% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -100.00% | -- | -- |
| Cost of Revenue | -20.25% | -3.94% | -17.73% | -2.75% | -18.83% |
| Gross Profit | 20.25% | 3.90% | 17.69% | 2.70% | 18.80% |
| SG&A Expenses | -11.23% | -13.18% | -9.90% | -4.15% | -13.16% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -18.07% | -6.24% | -15.85% | -3.13% | -17.53% |
| Operating Income | 18.07% | 6.21% | 15.83% | 3.10% | 17.50% |
| Income Before Tax | 23.23% | 8.10% | 30.64% | -6.43% | 16.25% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 23.23% | 8.10% | 30.12% | -6.43% | 16.25% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 23.23% | 8.10% | 30.12% | -6.43% | 16.25% |
| EBIT | 18.07% | 6.21% | 15.83% | 3.10% | 17.50% |
| EBITDA | 18.26% | 5.85% | 16.28% | 2.67% | 18.33% |
| EPS Basic | 33.36% | 27.82% | 44.15% | 14.70% | 35.30% |
| Normalized Basic EPS | 31.32% | 27.81% | 32.89% | 24.89% | 40.17% |
| EPS Diluted | 33.36% | 27.82% | 44.15% | 14.70% | 35.30% |
| Normalized Diluted EPS | 31.32% | 27.81% | 32.89% | 24.89% | 40.17% |
| Average Basic Shares Outstanding | 15.21% | 27.33% | 25.09% | 24.78% | 29.45% |
| Average Diluted Shares Outstanding | 15.21% | 27.33% | 25.09% | 24.78% | 29.45% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |